Factor IX pharmacokinetic estimates stratified by age and factor IX–antigen status3-150
| . | No. . | Incremental recovery, % . | FIX activity rise, IU/dL . | Half-life, h . |
|---|---|---|---|---|
| Age, y | ||||
| < 15 | 19 | 29.8 ± 9.9 (15.3-50.4) | 0.66 ± 0.22 (0.34-1.12) | 20.2 ± 4.0 (14.2-28.2) |
| 15-40 | 28 | 34.7 ± 9.2 (18.0-57.6) | 0.77 ± 0.20 (0.4-1.28) | 19.4 ± 5.5 (12.4-36.4) |
| > 40 | 9 | 37.7 ± 12.3 (23.3-62.2) | 0.84 ± 0.27 (0.52-1.38) | 17.2 ± 4.8 (11.1-25.0) |
| Factor IX antigen | ||||
| Positive | 22 | 36.9 ± 11.0 (17.1-62.2) | 0.82 ± 0.25 (0.38-1.38) | 18.7 ± 6.2 (11.1-36.4) |
| Negative | 33 | 31.0 ± 8.9 (15.3-50.4) | 0.69 ± 0.20 (0.34-1.12) | 19.8 ± 4.1 (12.7-28.2) |
| . | No. . | Incremental recovery, % . | FIX activity rise, IU/dL . | Half-life, h . |
|---|---|---|---|---|
| Age, y | ||||
| < 15 | 19 | 29.8 ± 9.9 (15.3-50.4) | 0.66 ± 0.22 (0.34-1.12) | 20.2 ± 4.0 (14.2-28.2) |
| 15-40 | 28 | 34.7 ± 9.2 (18.0-57.6) | 0.77 ± 0.20 (0.4-1.28) | 19.4 ± 5.5 (12.4-36.4) |
| > 40 | 9 | 37.7 ± 12.3 (23.3-62.2) | 0.84 ± 0.27 (0.52-1.38) | 17.2 ± 4.8 (11.1-25.0) |
| Factor IX antigen | ||||
| Positive | 22 | 36.9 ± 11.0 (17.1-62.2) | 0.82 ± 0.25 (0.38-1.38) | 18.7 ± 6.2 (11.1-36.4) |
| Negative | 33 | 31.0 ± 8.9 (15.3-50.4) | 0.69 ± 0.20 (0.34-1.12) | 19.8 ± 4.1 (12.7-28.2) |
Values represent the mean ± SD; range is shown in parentheses.
Assay interference precluded assessment of factor IX–antigen status in one patient.